Curis Analyst Price Targets - Benzinga

Curis Inc

CRISNASDAQ

Trade with Public

Trade with Public

$0.7139

0.05298%

Últ. Act.: Nov 4, 5:12 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

Curis Analyst Price Targets - Benzinga

Curis Analyst Price Targets

Wall Street analyst price targets and consensus rating for Curis (CRIS).

Price Target Range — 9 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$306Upside to Avg. PT+23080.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	HC Wainwright & Co.	Sara Nik	Maintained	Buy	$43
Jul 24, 2026	HC Wainwright & Co.	Sara Nik	PT Raise	Buy	$17→$43
Mar 20, 2026	HC Wainwright & Co.	Sara Nik	Maintained	Buy	$340
May 19, 2025	HC Wainwright & Co.	Joseph Pantginis	Assumes	Buy	$340
Mar 31, 2025	HC Wainwright & Co.	Edward White	PT Cut	Buy	$400→$320
Dec 10, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$400
Nov 15, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$400
Nov 1, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$520→$400
Sep 27, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$520
Aug 1, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$520
May 15, 2024	Truist Securities	Robyn Karnauskas	Maintained	Buy	$520
May 15, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$520
May 15, 2024	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	—
May 8, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$520
Feb 9, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$1020→$520
Nov 17, 2023	Truist Securities	Robyn Karnauskas	Initiate	Buy	$520

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $43 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $43 price target.

Benzinga Newsdesk

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis gained attention after positive emavusertib data as analyst raised its price target to $43 and highlighted upcoming trial catalysts.

Vandana Singh

PRO
HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $43

HC Wainwright & Co. analyst Sara Nik maintains Curis (NASDAQ:CRIS) with a Buy and raises the price target from $17 to $43.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $17 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $17 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Curis at Buy, Announces Price Target of $17

HC Wainwright & Co. analyst Joseph Pantginis assumes Curis (NASDAQ:CRIS) with a Buy rating and announces Price Target of $17.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $16

HC Wainwright & Co. analyst Edward White maintains Curis (NASDAQ:CRIS) with a Buy and lowers the price target from $20 to $16.

Benzinga Newsdesk